Анестезиология и реаниматология 1-2, 2018 Анестезиология и реаниматология

Haematol. 
1987;67(3):365-368.
81. Stansbury LG, Hess AS, Thompson K, et al. The clinical significance of 
platelet counts in the first 24 hours after severe injury. Transfusion. 
2013;53(4):783-789.
82. Johansson PI, Stensballe J, Rosenberg I, et al. Proactive administration of 
platelets and plasma for patients with a ruptured abdominal aortic aneurysm: 
evaluating a change in transfusion practice. Transfusion. 2007;47(4):593-598.
83. Joseph B, Aziz H, Zangbar B, et al. Acquired coagulopathy of traumatic brain 
injury defined by routine laboratory tests: which laboratory values matter? J 
Trauma Acute Care Surg.
2014;76(1):121-125.
84. Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coag-
ulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? Jour-
nal of Trauma. 
2008;65(2):261-270.
85. Nekludov M, Bellander BM, Blomback M, Wallen HN. Platelet dysfunction in 
patients with severe traumatic brain injury. J Neurotrauma. 2007;24(11):1699-1706.
86. Wohlauer MV, Moore EE, Thomas S, et al. Early platelet dysfunction: an 
unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg. 
2012;214(5):739-746.
87. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet 
to red blood cell ratios improves outcome in 466 massively transfused civil-
ian trauma patients. Ann Surg. 2008;248(3):447-458.
88. Zink KA, Sambasivan CN, Holcomb JB, et al. A high ratio of plasma and 
platelets to packed red blood cells in the first 6 hours of massive transfusion 
improves outcomes in a large multicenter study. Am J Surg. 2009;197(5):565-
570. discussion 570.
89. McQuilten ZK, Crighton G, Engelbrecht, et al. Transfusion interventions in 
critical bleeding requiring massive transfusion: a systematic review. Transfus 
Med Rev. 
2015;29(2):127-137.
90. Ho KM, Leonard AD. Concentration-dependent effect of hypocalcaemia 
on mortality of patients with critical bleeding requiring massive transfusion: 
a cohort study. Anaesth Intensive Care. 2011;39(1):46-54.

---

79
RUSSIAN JOURNAL OF ANAESTHESIOLOGY AND REANIMATOLOGY 1—2, 2018
91. Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trau-
ma: a review. The influence of acidosis, hypocalcemia, anemia, and hypo-
thermia on functional hemostasis in trauma. J Trauma. 2008;65(4):951-960.
92. Perkins JG, Cap AP, Weiss BM, et al. Massive transfusion and nonsurgical 
hemostatic agents. Crit Care Med. 2008;36(7 suppl):325-339.
93. Quinlan DJ, Eikelboom JW, Weitz JI. Four-factor prothrombin complex 
concentrate for urgent reversal of vitamin K antagonists in patients with ma-
jor bleeding. Circulation. 2013;128(11):1179-1181.
94. Sarode R, Milling Jr TJ, Refaai MA, et al. Efficacy and safety of a 4-factor 
prothrombin complex concentrate in patients on vitamin K antagonists pre-
senting with major bleeding: a randomized, plasma-controlled, phase IIIb 
study. Circulation. 2013;128(11):1234-1243.
95. Goldstein JN, Refaai MA, Milling Jr TJ, et al. Four-factor prothrombin com-
plex concentrate versus plasma for rapid vitamin K antagonist reversal in pa-
tients needing urgent surgical or invasive interventions: a phase 3b, open-la-
bel, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077-2087.
96. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and 
outcome in treated neurocritical care patients with intracerebral hemorrhage 
related to oral anticoagulant therapy: comparison of acute treatment strate-
gies using vitamin K, fresh frozen plasma, and prothrombin complex con-
centrates. Stroke. 2006;37(6):1465-1470.
97. Edavettal M, Rogers A, Rogers F, et al. Prothrombin complex concentrate 
accelerates international normalized ratio reversal and diminishes the exten-
sion of intracranial hemorrhage in geriatric trauma patients. Am Surg. 
2014;80(4):372-376.
98. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (war-
farin): third edition — 2005 update. Br J Haematol. 2006;132(3):277-285.
99. Knudson MM, Cohen MJ, Reidy R, et al. Trauma, transfusions, and use of 
recombinant factor VIIa: a multicenter case registry report of 380 patients 
from the Western Trauma Association. J Am Coll Surg. 2011;212(1):87-95.
100. Mitra B, Cameron PA, Parr MJ, Phillips L. Recombinant factor VIIa in trau-
ma patients with the ‘triad of death’. Injury. 2012;43(9):1409-1414.
101. Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: ef-
ficacy and safety of recombinant activated Factor VII in the management of 
refractory traumatic hemorrhage. J Trauma. 2010;69(3):489-500.
102. British Committee for Standards in Haematology. Guidelines for the use of 
platelet transfusions. British Journal of Haematology. 2017;176:365-394.
103. Клинические рекомендации по диагностике и лечению атипичного гемо-
литико-уремического синдрома.
Научное общество нефрологов России. 
2015. [Klinicheskie rekomendatsii po diagnostike i lecheniyu atipichnogo gem-
olitiko-uremicheskogo sindroma
. Nauchnoe obshhestvo nefrologov Rossii. 
2015.].
104. Решетняк Т.М. Лечение антифосфолипидного синдрома: современ-
ные стандарты. Тромбоз, гемостаз и реология. 2016;1:11-20. [Reshet-
nyak T.M. Treatment of antiphospholipid syndrome: modern standards. 
Tromboz, gemostaz i Reologia.
2016;1:11-20.].
105. Coppola A, Windyga J, Tufano A, et al. Treatment for preventing bleeding 
in people with haemophilia or other congenital bleeding disorders undergo-
ing surgery. Cochrane Database Syst Rev. 2015;2:CD009961.
106. Santagostino E, Escobar M, Ozelo M, et al. Recombinant activated factor 
VII in the treatment of bleeds and for the prevention of surgery-related bleed-
ing in congenital haemophilia with inhibitors. Blood Rev. 2015;29(suppl 1):9-
18.
107. Tran HT, Sorensen B, Rea CJ, et al. Tranexamic acid as adjunct therapy to 
bypassing agents in haemophilia A patients with inhibitors. Haemophilia. 
2014;20:369-375.
108. Neff AT, Sidonio RF Jr. Management of VWD. Hematology Am Soc Hema-
tol Educ Program. 
2014;536-541.
109. Leissinger C, Carcao M, Gill JC, et al. Desmopressin (DDAVP) in the man-
agement of patients with congenital bleeding disorders. Haemophilia. 
2014;20:158-167.
110. Windyga J, Dolan G, Altisent C, et al. Practical aspects of DDAVP use in 
patients with von Willebrand Disease undergoing invasive procedures: a Eu-
ropean survey. Haemophilia. 2016;22:110-120.